Drug Guide
 

Tofacitinib

Bookmark
  •  
    Oral
    Tofacitinib
    Xeljanz 
     
    Inhibits JAK1, JAK2 and JAK3
    • Mechanism of Action
    • Inhibits Janus Kinases (JAK1, JAK2 and JAK3), a group of non-receptor tyrosine kinases involved in signalling downstream to cytokine receptors in immune and haematopoietic cells.

Clinical Use

    • Indication
    • Moderate to severe rheumatoid arthritis refractory to methotrexate.
    • Adverse Effects
    • Severe infections (particularly respiratory and urinary tract infections)
    • Anaemia
    • Headache
    • Dizziness
    • Nausea / vomiting / diarrhoea
    • Hypertension
    • Hypercholesterolaemia
    • Abdominal pain
Want more info like this?
  • Your electronic clinical medicine handbook
  • Guides to help pass your exams
  • Tools every medical student needs
  • Quick diagrams to have the answers, fast
  • Quizzes to test your knowledge
Explore
   
 
Feedback